

Resource Summary Report

Generated by NIF on Jul 31, 2026

Brilliant Violet 605(TM) anti-mouse CD25

RRID:AB_2563059

Type: Antibody

Proper Citation

BioLegend Cat# 102036, RRID:AB_2563059

Antibody Information

URL: http://antibodyregistry.org/AB_2563059

Proper Citation: BioLegend Cat# 102036, RRID:AB_2563059

Target Antigen: CD25

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-mouse CD25

Description: This monoclonal targets CD25

Target Organism: mouse

Clone ID: Clone PC61

Antibody ID: AB_2563059

Vendor: BioLegend

Catalog Number: 102036

Alternative Catalog Numbers: 102035

Record Creation Time: 20250819T234855+0000

Record Last Update: 20250820T063012+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-mouse CD25.

No alerts have been found for Brilliant Violet 605(TM) anti-mouse CD25.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Mitchell-Flack M, et al. (2026) The ionotropic AMPA receptor contributes to autoimmunity via altered regulatory T cell differentiation. *iScience*, 29(1), 114267.

Ver Heul AM, et al. (2025) RAG suppresses group 2 innate lymphoid cells. *eLife*, 13.

Stinson JA, et al. (2025) Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control. *Molecular cancer therapeutics*, 24(1), 118.

Kimura N, et al. (2025) Regulatory T cell stability determines the efficiency of bile duct regeneration during cholangitis. *Cell reports*, 44(11), 116557.

Zhong J, et al. (2024) Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. *Cancer cell*, 42(6), 968.

Li Z, et al. (2024) Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. *Cell*, 187(3), 624.

Zhang YC, et al. (2024) Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies. *Theranostics*, 14(16), 6249.

Cardinez C, et al. (2024) IKK2 controls the inflammatory potential of tissue-resident regulatory T cells in a murine gain of function model. *Nature communications*, 15(1), 2345.

Shouse AN, et al. (2024) Interleukin-2 receptor signaling acts as a checkpoint that influences the distribution of regulatory T cell subsets. *iScience*, 27(12), 111248.

Mandarano AH, et al. (2023) DRAK2 contributes to type 1 diabetes by negatively regulating IL-2 sensitivity to alter regulatory T cell development. *Cell reports*, 42(2), 112106.

Miyai Y, et al. (2022) Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. *Life science alliance*, 5(6).

Farrand K, et al. (2022) Using Full-Spectrum Flow Cytometry to Phenotype Memory T and NKT Cell Subsets with Optimized Tissue-Specific Preparation Protocols. *Current protocols*, 2(7), e482.

Zhou X, et al. (2021) Stearoyl-CoA Desaturase-Mediated Monounsaturated Fatty Acid Availability Supports Humoral Immunity. *Cell reports*, 34(1), 108601.

Paiva RA, et al. (2021) Self-renewal of double-negative 3 early thymocytes enables thymus autonomy but compromises the β -selection checkpoint. *Cell reports*, 35(2), 108967.

Sadik A, et al. (2020) IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. *Cell*, 182(5), 1252.

Ramos CV, et al. (2020) Cell Competition, the Kinetics of Thymopoiesis, and Thymus Cellularity Are Regulated by Double-Negative 2 to 3 Early Thymocytes. *Cell reports*, 32(3), 107910.

Dammeijer F, et al. (2020) The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. *Cancer cell*, 38(5), 685.

Angiari S, et al. (2020) Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4⁺ T Cell Pathogenicity and Suppresses Autoimmunity. *Cell metabolism*, 31(2), 391.